SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: Guggenheim Securities Emerging Outlook: Biotech SummitDate: February 11, 2026Time: 10:30 a.m. ETFormat: Fireside ChatLocation: New York, NY Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: February 25, 2026Time: 8:40 a.m. ETFormat: Fireside Chat Location: VirtualTo access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company’s website at www.sab.bio. About SAB BIOSAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimm
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- SAB BIO Strengthens Board of Directors with Appointment of New Chair and New DirectorGlobeNewswire
- SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.MarketBeat
SABS
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- SABS's page on the SEC website